Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II atezolizumab + carboplatin + nab-paclitaxel in ECOG PS 2 advanced non-squamous NSCLC
jRCTs041210030Phase 2Active, not recruiting
- Start
- Aug 2021
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of atezolizumab, carboplatin and paclitaxel in non-small cell lung cancer (NSCLC). Primary endpoint: Overall response rate. Started Aug 2021; status: active, not recruiting.
02
Drugs
atezolizumabcarboplatinpaclitaxel
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCTs041210030.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs041210030.